Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences develops neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Its news commonly centers on EB-003, a lead candidate from the EVM301 Series designed to promote neuroplasticity without hallucinogenic effects and to modulate 5-HT2A and 5-HT1B receptors. Company updates also discuss preclinical models tied to PTSD, depression, anxiety and related neuropsychiatric conditions.
Recurring announcements include intellectual-property activity for the EVM301 and EVM401 Series, trademark registrations, corporate and financial results, and capital actions involving common stock, pre-funded warrants and other warrants. Enveric also reports business-development and conference activity around non-hallucinogenic and psychedelic-inspired therapeutic approaches.
Enveric Biosciences (NASDAQ: ENVB) announced participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York City on September 12-14, 2022. President & COO Avani Kanubaddi will present on September 14 at 2:00 p.m. ET. Attendees can register here. Enveric focuses on developing innovative psychedelic-inspired medicines for mental health.
Enveric Biosciences (NASDAQ: ENVB) has appointed three experienced leaders to its Board of Directors: Michael D. Webb, Bevin O’Neil, and Frank Pasqualone. These new board members bring decades of expertise in healthcare, business operations, and global market dynamics. Dr. Joseph Tucker, CEO, expressed enthusiasm for their contributions at this pivotal time for the company, which is focused on developing psychedelic-inspired mental health medicines.
Enveric Biosciences, Inc. (NASDAQ: ENVB) has completed a registered direct offering of 375,000 shares of common stock, raising approximately $8 million before expenses. Additionally, a private placement was conducted for 625,000 shares under similar terms. The offerings included preferred investment options that allow the purchase of an equal number of shares at an exercise price of $7.78. Proceeds will support working capital and corporate purposes. The company has also amended existing warrants to reduce their exercise price to $7.78 from $27.50.
Enveric Biosciences (NASDAQ: ENVB) has entered into definitive agreements for the purchase of 1,000,000 shares of its common stock through a registered direct offering and private placement, priced at $8.00 per share. The total expected gross proceeds from these offerings are approximately $8 million, intended for working capital and corporate purposes. Additionally, existing warrants will be amended to reduce their exercise price to $7.78 per share. The closing is anticipated around July 26, 2022, subject to customary conditions.
Enveric Biosciences (NASDAQ: ENVB) announced a 1-for-50 reverse stock split effective July 14, 2022. This adjustment will reduce the outstanding shares from approximately 52.7 million to 1.05 million. Shareholders will not need to exchange certificates, as adjustments will be made automatically for shares held in brokerage accounts. This split is aimed at improving the company's stock price and maintaining its listing on the Nasdaq Capital Market. The company focuses on developing psychedelic-inspired mental health medicines.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on psychedelic-inspired mental health treatments, announced participation in three key conferences: the A.G.P. Summer Healthcare Conference on June 21-22, the Gravitas Los Angeles Summit on June 22, and the H.C. Wainwright Mental Health Conference on June 27. CEO Dr. Joseph Tucker will represent the company at these events, highlighting its commitment to developing innovative solutions for mental health issues affecting patients globally.
Enveric Biosciences (NASDAQ: ENVB) announced that President Avani Kanubaddi will participate in the virtual Microdose Psychedelic Capital Conference on May 26, 2022, at 4:05 p.m. ET. During the panel titled 'The Spinoffs - Divide and Conquer', topics will include recent spinoffs among publicly traded companies. Interested attendees can register here. For further inquiries or one-on-one meetings, contact KCSA Strategic Communications at EnvericBio@kcsa.com.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on psychedelic-inspired mental health treatments, will have CEO Dr. Joseph Tucker participate virtually in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. His presentation will be available on-demand starting May 24 at 7:00 a.m. ET. This event highlights Enveric's dedication to advancing mental health solutions, aiming to assist patients with conditions like PTSD and cancer-related distress. For further details or to arrange a meeting with management, interested parties should contact H.C. Wainwright.
Enveric Biosciences (NASDAQ: ENVB) announced plans to spin off its cannabinoid pipeline into a subsidiary, Acanna Therapeutics Inc., through a dividend to shareholders. This strategic move aims to create two separate biotechnology companies focusing on psychedelic-inspired mental health treatments and cannabinoid therapies. The spin-off is contingent on Acanna meeting Nasdaq listing qualifications and has secured $1 million in initial funding, with potential additional funding of $4 million upon completion. The goal is to enhance resource allocation and value creation for both companies.
Enveric Biosciences (NASDAQ: ENVB) is hosting a virtual fireside chat with Chief Medical Officer Dr. Bob Dagher on May 17, 2022, at 10:00 a.m. EDT. Dr. Dagher, with over 20 years of experience in neuroscience, will discuss the psychedelic industry and Cancer Related Distress, showcasing Enveric's unique approach to psychedelic therapeutics. He will also outline anticipated milestones for 2022. Interested participants can register for the event here.